Opinion|Videos|October 24, 2024
Osimertinib: Evolution of Treatment from Refractory Disease to Prevention of Drivers of Disease Progression
Author(s)Hatim Husain, MD
Panelist discusses how agents such as osimertinib, initially developed to target resistance mechanisms in refractory disease, are now being used proactively to prevent drivers of disease progression.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Agents such as osimertinib that first targeted resistance mechanisms in refractory disease are now being used to prevent drivers of disease progression.
- Please discuss your thoughts about this strategy.
Advertisement
Related to this article
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
The FDA approved an sNDA updating the taletrectinib label with a 49.7-month median duration of response from TRUST-I in ROS1-positive NSCLC.
KEYNOTE-D46 shows sacituzumab govitecan plus pembrolizumab misses PFS/OS targets in PD-L1–high metastatic NSCLC, despite higher responses and toxicity.
The phase 3 DESTINY-Lung04 trial showed first-line trastuzumab deruxtecan extended PFS in patients with HER2-mutant NSCLC.
Updated PRESERVE-003 data showed gotistobart nearly doubled median OS vs docetaxel in previously treated squamous NSCLC.
Osimertinib was associated with a 47% reduction in risk of death among patients with stage II-IIIA EGFR-mutated non–small cell lung cancer at 8 years.
First-line amivantamab plus chemotherapy produced the longest reported median OS in EGFR exon 20 insertion-positive advanced NSCLC in the phase 3 PAPILLON trial.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Imlunestrant Plus Abemaciclib in ESR1-Mutated Breast Cancer
2
Daraxonrasib Combo Receives FDA Breakthrough Status in First-Line PDAC
3
Mosunetuzumab Combo Improves PFS in R/R Follicular Lymphoma
4
Data Increasingly Favor BCMA-Directed Therapy For Early-Relapse Myeloma
5